[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100059421":3},{"organization":4,"armGroups":7,"interventions":22,"overallOfficials":42,"centralContacts":50,"locations":51,"responsibleParty":216,"collaborators":218,"id":221,"slug":222,"hasResults":223,"nctId":224,"briefTitle":225,"officialTitle":226,"acronym":50,"eligibilityCriteria":227,"healthyVolunteers":228,"sex":229,"minAge":230,"maxAge":231,"enrollmentInfo":232,"targetDuration":50,"studyType":235,"phases":236,"briefSummary":239,"conditions":240,"keywords":242,"overallStatus":252,"whyStopped":50,"lastUpdateSubmitDate":253,"lastUpdatePostDateStruct":254,"startDateStruct":256,"completionDateStruct":258,"leadSponsor":260,"locationsCount":261},{"fullName":5,"class":6},"National Institute of Allergy and Infectious Diseases (NIAID)","NIH",[8,16,19],{"label":9,"type":10,"description":11,"interventionNames":12},"Age Group 1: 90 days to \u003C 3 years of age (FTC, EFV, ddI)","EXPERIMENTAL","Emtricitabine (FTC), Efavirenz (EFV) and Didanosine (ddI) together once daily",[13,14,15],"Drug: Didanosine (ddI)","Drug: Efavirenz (EFV)","Drug: Emtricitabine (FTC)",{"label":17,"type":10,"description":11,"interventionNames":18},"Age Group 2: 3 to 12 years of age (FTC, EFV, ddI)",[13,14,15],{"label":20,"type":10,"description":11,"interventionNames":21},"Age Group 2: 13 to 21 years of age (FTC, EFV, ddI)",[13,14,15],[23,30,36],{"type":24,"name":25,"description":26,"armGroupLabels":27,"otherNames":28},"DRUG","Didanosine (ddI)","Antiretroviral Didanosine (ddI) : 240 mg\u002Fm\\^2 up to a maximum of 400 mg once daily",[9,20,17],[29],"Videx, Videx EC",{"type":24,"name":31,"description":32,"armGroupLabels":33,"otherNames":34},"Efavirenz (EFV)","Antiretroviral For Age Group 1 Efavirenz (EFV): dose adjusted for body size and for Age Groups 2 and 3 Efavirenz (EFV): up to a maximum of 600 mg once daily as a capsule ot 720 mg as an oral solution",[9,20,17],[35],"Sustiva",{"type":24,"name":37,"description":38,"armGroupLabels":39,"otherNames":40},"Emtricitabine (FTC)","Antiretroviral Emtricitabine (FTC): 6 mg\u002FKg up to a maximum of 200 mg once daily",[9,20,17],[41],"Emtriva",[43,47],{"name":44,"affiliation":45,"role":46},"Ross E. McKinney, Jr., MD","Duke University","STUDY_CHAIR",{"name":48,"affiliation":49,"role":46},"Mobeen H. Rathore, MD","Pediatric Infectious Diseases\u002FImmunology, University of Florida Health Science Center",null,[52,64,73,83,93,103,112,122,127,137,146,155,160,169,179,189,199,210],{"facility":53,"status":50,"city":54,"state":55,"zip":50,"country":56,"countryCode":57,"cosmosGeoPoint":58,"geoPoint":63,"contacts":50},"UCSD Maternal, Child, and Adolescent HIV CRS","San Diego","California","United States","US",{"type":59,"coordinates":60},"Point",[61,62],-117.16472,32.71571,{"lat":62,"lon":61},{"facility":65,"status":50,"city":66,"state":55,"zip":67,"country":56,"countryCode":57,"cosmosGeoPoint":68,"geoPoint":72,"contacts":50},"UCSF Pediatric AIDS CRS","San Francisco","941430105",{"type":59,"coordinates":69},[70,71],-122.41942,37.77493,{"lat":71,"lon":70},{"facility":74,"status":50,"city":75,"state":76,"zip":77,"country":56,"countryCode":57,"cosmosGeoPoint":78,"geoPoint":82,"contacts":50},"Univ. of Colorado Denver NICHD CRS","Aurora","Colorado","802181088",{"type":59,"coordinates":79},[80,81],-104.83192,39.72943,{"lat":81,"lon":80},{"facility":84,"status":50,"city":85,"state":86,"zip":87,"country":56,"countryCode":57,"cosmosGeoPoint":88,"geoPoint":92,"contacts":50},"Howard Univ. Washington DC NICHD CRS","Washington D.C.","District of Columbia","20060",{"type":59,"coordinates":89},[90,91],-77.03637,38.89511,{"lat":91,"lon":90},{"facility":94,"status":50,"city":95,"state":96,"zip":97,"country":56,"countryCode":57,"cosmosGeoPoint":98,"geoPoint":102,"contacts":50},"Univ. of Florida Jacksonville NICHD CRS","Jacksonville","Florida","32209",{"type":59,"coordinates":99},[100,101],-81.65565,30.33218,{"lat":101,"lon":100},{"facility":104,"status":50,"city":105,"state":96,"zip":106,"country":56,"countryCode":57,"cosmosGeoPoint":107,"geoPoint":111,"contacts":50},"Univ. of Miami Ped. Perinatal HIV\u002FAIDS CRS","Miami","33161",{"type":59,"coordinates":108},[109,110],-80.19366,25.77427,{"lat":110,"lon":109},{"facility":113,"status":50,"city":114,"state":115,"zip":116,"country":56,"countryCode":57,"cosmosGeoPoint":117,"geoPoint":121,"contacts":50},"Chicago Children's CRS","Chicago","Illinois","606143394",{"type":59,"coordinates":118},[119,120],-87.65005,41.85003,{"lat":120,"lon":119},{"facility":123,"status":50,"city":114,"state":115,"zip":50,"country":56,"countryCode":57,"cosmosGeoPoint":124,"geoPoint":126,"contacts":50},"Rush Univ. Cook County Hosp. Chicago NICHD CRS",{"type":59,"coordinates":125},[119,120],{"lat":120,"lon":119},{"facility":128,"status":50,"city":129,"state":130,"zip":131,"country":56,"countryCode":57,"cosmosGeoPoint":132,"geoPoint":136,"contacts":50},"Children's Hosp. of Boston NICHD CRS","Boston","Massachusetts","021155724",{"type":59,"coordinates":133},[134,135],-71.05977,42.35843,{"lat":135,"lon":134},{"facility":138,"status":50,"city":139,"state":130,"zip":140,"country":56,"countryCode":57,"cosmosGeoPoint":141,"geoPoint":145,"contacts":50},"WNE Maternal Pediatric Adolescent AIDS CRS","Worcester","016550001",{"type":59,"coordinates":142},[143,144],-71.80229,42.26259,{"lat":144,"lon":143},{"facility":147,"status":50,"city":148,"state":148,"zip":149,"country":56,"countryCode":57,"cosmosGeoPoint":150,"geoPoint":154,"contacts":50},"Nyu Ny Nichd Crs","New York","10016",{"type":59,"coordinates":151},[152,153],-74.00597,40.71427,{"lat":153,"lon":152},{"facility":156,"status":50,"city":148,"state":148,"zip":50,"country":56,"countryCode":57,"cosmosGeoPoint":157,"geoPoint":159,"contacts":50},"Harlem Hosp. Ctr. NY NICHD CRS",{"type":59,"coordinates":158},[152,153],{"lat":153,"lon":152},{"facility":161,"status":50,"city":162,"state":148,"zip":163,"country":56,"countryCode":57,"cosmosGeoPoint":164,"geoPoint":168,"contacts":50},"SUNY Upstate Med. Univ., Dept. of Peds.","Syracuse","13210",{"type":59,"coordinates":165},[166,167],-76.14742,43.04812,{"lat":167,"lon":166},{"facility":170,"status":50,"city":171,"state":172,"zip":173,"country":56,"countryCode":57,"cosmosGeoPoint":174,"geoPoint":178,"contacts":50},"DUMC Ped. CRS","Durham","North Carolina","277103499",{"type":59,"coordinates":175},[176,177],-78.89862,35.99403,{"lat":177,"lon":176},{"facility":180,"status":50,"city":181,"state":182,"zip":183,"country":56,"countryCode":57,"cosmosGeoPoint":184,"geoPoint":188,"contacts":50},"St. Jude\u002FUTHSC CRS","Memphis","Tennessee","381052794",{"type":59,"coordinates":185},[186,187],-90.04898,35.14953,{"lat":187,"lon":186},{"facility":190,"status":50,"city":191,"state":192,"zip":193,"country":56,"countryCode":57,"cosmosGeoPoint":194,"geoPoint":198,"contacts":50},"Texas Children's Hosp. CRS","Houston","Texas","77030",{"type":59,"coordinates":195},[196,197],-95.36327,29.76328,{"lat":197,"lon":196},{"facility":200,"status":50,"city":201,"state":50,"zip":202,"country":203,"countryCode":204,"cosmosGeoPoint":205,"geoPoint":209,"contacts":50},"Univ. of Puerto Rico Ped. HIV\u002FAIDS Research Program CRS","San Juan","009365067","Puerto Rico","PR",{"type":59,"coordinates":206},[207,208],-66.10572,18.46633,{"lat":208,"lon":207},{"facility":211,"status":50,"city":201,"state":50,"zip":212,"country":203,"countryCode":204,"cosmosGeoPoint":213,"geoPoint":215,"contacts":50},"San Juan City Hosp. PR NICHD CRS","009367344",{"type":59,"coordinates":214},[207,208],{"lat":208,"lon":207},{"type":217,"investigatorFullName":50,"investigatorTitle":50,"investigatorAffiliation":50,"oldNameTitle":50,"oldOrganization":50},"SPONSOR",[219],{"name":220,"class":6},"Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","100059421","phase-1-safety-and-effectiveness-of-emtricitabine-efavirenz-and-didanosine-in-hiv-infected-children-who-have-taken-few-or-no-anti-hiv-drugs-100059421",true,"NCT00016718","Safety and Effectiveness of Emtricitabine, Efavirenz, and Didanosine in HIV Infected Children Who Have Taken Few or No Anti-HIV Drugs","An Open-Label Study to Evaluate the Safety, Tolerance, Antiviral Activity, and Pharmacokinetics of Emtricitabine in Combination With Efavirenz and Didanosine in a Once-Daily Regimen in HIV Infected, Antiretroviral Therapy Naive or Very Limited Antiretroviral Exposed Pediatric Subjects","Inclusion Criteria:\n\n* HIV infected\n* Antiretroviral naive OR have received no more than 56 days of drugs to prevent mother-to-child transmission of HIV OR have received less than 7 total days of antiretroviral therapy\n* Viral load of 5,000 copies\u002Fml or more\n* Any Center for Disease Control (CDC) classification and immune status\n* Able to swallow study medications\n* Parent or guardian willing to provide informed consent, if applicable\n* Willing to use acceptable forms of contraception\n* female subjects of childbearing potential with a negative serum beta human chronic gonadotropin\n\nExclusion Criteria:\n\n* Allergic to study medications or their formulations\n* Kidney disease\n* Positive for hepatitis B or C\n* Acute opportunistic infection (OI) or bacterial infection requiring treatment at study entry\n* Taking drugs to treat tuberculosis\n* Taking anti-HIV drugs other than those included in this study\n* Hemoglobin \\>= grade 3 at screening\n* Absolute Neutrophil counts \\>= grade 2 at screening\n* Platelets \\>= Grade 2 at screening\n* Bilirubin \\>= Grade 2 at screening\n* SGOT (AST), SGPT(ALT) \\>= Grade 2 at screening\n* Non-fasting triglycerides \\>= Grade 2 at screening. Confirmed by a 2nd determination \\>=100 mg\u002Fdl at fasting state\n* Pancreatic amylase or total amylase+ lipase \\>= Grade 2 at screening\n* Taking any investigational drugs\n* Anti-cancer drugs within 1 year of study screening\n* Serious medical event within 21 days of study screening\n* Active or history of pancreatitis\n* Require certain medications. Patients requiring short courses of steroids (less than 14 days) for asthma are not excluded.\n* Active or history of significant peripheral neuropathy\n* Difficulty with food or severe chronic diarrhea within 30 days before study entry\n* Unable to eat at least 1 meal per day (or to feed at least 3 times per day, for infants) because of chronic nausea, vomiting, swallowing problems, or stomach upset\n* Unable to swallow oral medications\n* Pregnant or breastfeeding",false,"ALL","90 Days","21 Years",{"count":233,"type":234},43,"ACTUAL","INTERVENTIONAL",[237,238],"PHASE1","PHASE2","Treatment of HIV-infected patients involves combining drugs from different classes of anti-HIV drugs. One preferred regimen for adults is 2 nucleoside reverse transcriptase inhibitors (NRTIs) and 1 protease inhibitor (PI). For children, this regimen may be too complicated or the drugs may be too difficult to take by mouth. The purpose of this study was to determine the long-term safety and effectiveness of daily didanosine (ddI), efavirenz (EFV), and emtricitabine (FTC) in pediatric patients who had taken few or no anti-HIV drugs.",[241],"HIV Infections",[243,244,245,246,247,248,249,250,251],"Didanosine","Drug Therapy, Combination","Drug Administration Schedule","Reverse Transcriptase Inhibitors","Anti-HIV Agents","Pharmacokinetics","Deoxycytidine","Efavirenz","Treatment Naive","COMPLETED","2021-11-03",{"date":255,"type":234},"2021-11-05",{"date":257,"type":50},"2001-08",{"date":259,"type":234},"2009-01",{"name":5,"class":6},18]